Autoantibodies against apolipoprotein A‐1 after COVID‐19 predict symptoms persistence
Arnaud G. L’Huillier, Nicolas Vuilleumier(University of Geneva), Sabine Yerly(Unknown), Christiane S. Eberhardt(University of Geneva), Klara M. Posfay‐Barbe(University Hospital of Geneva), Claire‐Anne Siegrist(University of Geneva), Stéphanie Baggio(University of Bern), Mayssam Nehme(University Hospital of Geneva), Laurent Kaiser(University Hospital of Geneva), Angela Huttner(University Hospital of Geneva), Benjamin Meyer(University of Geneva), Diego O. Andrey(University of Geneva), Idris Guessous(University of Geneva), Sabrina Pagano(University Hospital of Geneva)
Cited by 28
Related Papers
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|5.8k
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
|The Lancet|2020|1.1k
CKD Prevalence Varies across the European General Population
|Journal of the American Society of Nephrology|2015|588
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
|Antimicrobial Resistance and Infection Control|2013|454
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
|New England Journal of Medicine|2015|412